[New York], [October 8, 2024] — ATP Ventures Partner, a biotech venture creation firm specializing in drug asset development, today announced the acquisition of Tupelo Brittany, a leading biotech consulting firm. This acquisition represents a strategic shift for ATP Ventures Partner, enhancing its capabilities in integrated company creation and accelerating the development of transformative therapies.
The merger will expand ATP Ventures Partner’s hands-on role in company formation and therapeutic asset development. By incorporating Tupelo Brittany’s expertise in business development, in-out licensing, deal-making, and financial strategies, ATP Ventures Partner will collaborate with visionary entrepreneurs through key milestones, from early-stage research to clinical development and market entry.
“This acquisition strengthens our ability to grow alongside founders, offering not only capital but also the expertise needed to bring life-changing therapies to market,” said Drew Zhu, Managing Partner at ATP Ventures Partner.
The acquisition aligns with ATP Ventures Partner’s mission to support early-stage ventures and scientists with the resources required to develop therapies for life-threatening diseases. Tupelo Brittany’s strengths in market insight, business intelligence, deal-making, and financial strategy will seamlessly integrate into ATP Ventures’ operations, reinforcing its commitment to scientific excellence.
The combined entity will operate under the ATP Ventures Partner brand, with a shared focus on advancing innovative ideas into life-saving therapies.
About ATP Ventures Partner
ATP Ventures Partner is a biotech venture creation firm specializing in drug asset development and company creation. ATP offers hands-on expertise in advancing drug candidates through clinical stages, with a focus on therapeutic areas including women’s health, mental health, anti-aging, metabolism/cardiovascular, ophthalmology, and artificial intelligence powered biotech. Portfolio companies include Flatbird Therapeutics.
About Tupelo Brittany
Tupelo Brittany is a biotech consulting firm known for delivering strategic advisory services, including fundraising support, business development, in-out licensing, deal-making strategies, market insight, business intelligence, and market development within the pharmaceutical and biotechnology sectors.
Media:Emily Johnson ir@atpvent.com
Source: ATP Ventures Partner
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.